Cite
HARVARD Citation
Reardon, D. et al. (2021). Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial. Cancer. 127 (10), pp. 1620-1629. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Reardon, D. et al. (2021). Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial. Cancer. 127 (10), pp. 1620-1629. [Online].